Sildenafil Citrate Powder, For Suspension
Product Images NDC 72205-059

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 72205-059). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle-label (Bottle Label)

This is a description for a medication called Sildenafil, which comes in the form of an oral suspension. The text provides instructions for storing and using the medication, as well as the dosage and potency of each bottle. The medication should be stored below 30°C before and after reconstitution, and discarded 60 days after reconstitution. The medication should be shaken well before each use, and comes in a grape flavor. The medication is manufactured by Novadoz Pharmaceuticals LLC and distributed by NDC. Recommended dosage information is available in the prescribing information.*

FDA Label Image

Carton-label (Carton Label)

This appears to be product packaging for Sildenafil Oral Suspension, which is to be reconstituted with water prior to use. The packaging includes information on dosage and storage, as well as manufacturing and distribution details. An oral dosing syringe and a press-in bottle adapter are also provided.*

FDA Label Image

Figure-1 (Figure 1)

FDA Label Image

Figure-10 (Figure 10)

This document appears to be reporting medical data including patient demographics, diagnostics, and treatment for a study. The data includes age, gender, walk distance, etiology, and PAH Class. There is mention of a Placabo and Sildenafil 20 mg TID. The results include mean PAR and PVRI, and show a change in the 6-minute walk distance.*

FDA Label Image

Figure-11 (Figure 11)

FDA Label Image

Figure-12 (Figure 12)

This appears to be a graph displaying the mean change in meters from a baseline at different time periods for three different treatments involving Sildenafil, with the standard error also included. Specific doses of Sildenafil (1mg TID, 5mg TID, and 20mg TID) were apparently given to participants. It is unclear what the study was evaluating.*

FDA Label Image

Figure-2 (Figure 2)

FDA Label Image

Figure-3 (Figure 3)

FDA Label Image

Figure-4 (Figure 4)

FDA Label Image

Figure-5 (Figure 5)

FDA Label Image

Figure-6 (Figure 6)

This looks like a chart or data display, showing estimated cumulative mortality rates in percentages for different doses or treatments. The chart shows different values for different "ids" or groups, labeled 1 through 5t. The mortality rates range from 25% to 96%, with corresponding values for high, medium, and low doses or treatments. There may be additional information or labels further above or below this chart that are not included in the text.*

FDA Label Image

Figure-7 (Figure 7)

This text provides a list of drugs and their interaction with Atorvastatin in terms of AUC and Cmax. The text also mentions fold change and 90% CI recommendations based on the interaction of each drug with Atorvastatin. In some cases, no dose adjustment is required, while in a few cases, co-administration is not recommended. The text also suggests that adding sildenafil to bosentan therapy does not have any benefit on exercise capacity.*

FDA Label Image

Figure-8 (Figure 8)

This is a chart listing drugs that interact with Acenocoumarol and the recommended dose adjustments for coadministration. The chart also provides information on the fold change and 90% CI for the drugs when combined with Acenocoumarol. Some drugs do not require any dose adjustments, while others are not recommended for coadministration. Some drugs have additional notes such as their impact on bleeding time or exercise capacity. Ritonavir's effect on Sildenafil PK is also mentioned.*

FDA Label Image

Figure-9 (Figure 9)

This document appears to be a chart or a graph depicting changes in Haseline (meters). The top row of numbers shows values of 80, 80, 40, and 20 on different occasions. The bottom part of the document is divided into three sections - Week 4, Week 8, and Week 12. Each section has different treatments labeled as Placebo, Sildenafil 20mg TID, Stidenatl 40mg TID, and Sfldenafil 80mg TID. It is unclear what this document is specifically referring to, but it may be related to a medical study or a clinical trial.*

FDA Label Image

Figure-a (Figure A)

FDA Label Image

Figure-b (Figure B)

FDA Label Image

Figure-c (Figure C)

FDA Label Image

Figure-d (Figure D)

FDA Label Image

Figure-e (Figure E)

FDA Label Image

Figure-f (Figure F)

FDA Label Image

Figure-g (Figure G)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.